Working together to exploit a rich seam of novel epigenetic targets for cancer
Session type: Parallel sessions
1University of Oxford, Oxford, UK
During my presentation, I will discuss:
- How we are pooling the expertise and infrastructure of several big pharmas, withdisease and clinical expertise, and patients resources in academia, to accelerate novel target identification.
- Novel epigenetic targets which are worth further exploration.
- How these efforts are facilitating science and proprietary programmes, including the creation of new biotechs.
- Our plans to establish a nationwide, human disease platform for novel epigenetic target prioritisation.